| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -4,937,046 | -5,955,802 | -3,218,481 | -6,676,281 |
| Stock-based compensation | 2,555 | 85,068 | 18,452 | 84,208 |
| Common stock issued for license agreement | - | 0 | 0 | - |
| Loss (gain) on disposal of fixed assets | - | -2,559 | 0 | 0 |
| Depreciation | 1,868 | 1,020 | 697 | 2,201 |
| Prepaid expenses and other current assets | 293,790 | -961,819 | -401,661 | 1,060,681 |
| Deferred offering costs | - | - | 43,700 | - |
| Accounts payable and accrued expenses | 577,795 | 1,809,866 | 667,201 | -934,614 |
| Net cash used in operating activities | -4,648,618 | -3,051,770 | -2,174,170 | -8,585,167 |
| Purchase of property and equipment | 6,179 | 18,175 | - | - |
| Net cash used in investing activities | -6,179 | -18,175 | - | - |
| Payments of deferred offering costs | - | 64,082 | 0 | 0 |
| Payments on notes payable | 96,218 | 30,791 | 90,974 | 175,788 |
| Proceeds from exercise of warrants | - | 0 | 844 | 2,783 |
| Proceeds from sale of common stock | - | 501,745 | 0 | 13,544,685 |
| Payments to stockholders for stock split round | 0 | 0 | 1,486 | 557 |
| Proceeds from subscription receivable | 0 | 0 | 0 | 882,539 |
| Proceeds from equity issuance | 500,878 | - | - | - |
| Net cash provided by financing activities | 404,660 | 406,872 | -91,616 | 14,253,662 |
| Net change in cash and cash equivalents | -4,250,137 | -2,663,073 | -2,265,786 | 5,668,495 |
| Cash and cash equivalents, at beginning of period | 7,201,014 | 9,864,087 | 6,461,378 | - |
| Cash and cash equivalents, at end of period | 2,950,877 | 7,201,014 | 9,864,087 | - |
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)